Skip to content
OpenCapital
Get started
Emergent Biosolutions logo

Emergent Biosolutions (EBS) Q1 2026 Earnings

EBS·Reported April 30, 2026·After market close

Emergent Biosolutions reported Q1 2026 revenue of $156.1M (-29.7% YoY), beat analyst consensus of $145.0M by $11.1M. Diluted EPS came in at $0.21 (-70.4% YoY), beat the $-0.25 consensus by $0.46.

Revenue
$156.1Mbeat by $11.1M
Consensus: $145.0M
Diluted EPS
$0.21beat by $0.46
Consensus: $-0.25
SEC

SEC Filings

Earnings release8-K · 0001367644-26-000051
Quarterly report10-Q · 0001367644-26-000065

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Emergent Biosolutions's Q1 2026 earnings report.

Emergent Biosolutions (EBS) reported Q1 2026 earnings on April 30, 2026 after market close.

Emergent Biosolutions reported revenue of $156.1M and diluted EPS of $0.21 for Q1 2026.

Revenue beat the consensus estimate of $145.0M by $11.1M. EPS beat the consensus estimate of $-0.25 by $0.46.

Compared to the same quarter a year prior, revenue declined 29.7% from $222.2M a year earlier and diluted EPS declined 70.4% from $0.71.

You can read the 8-K earnings release (0001367644-26-000051) and the 10-Q periodic report (0001367644-26-000065) directly on SEC EDGAR. The filing index links above go to sec.gov.